Growing interest and innovation will drive adhesion barrier market, according to Millennium Research Group
WALTHAM, Mass., Feb. 2 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers 2009 report, growing surgeon interest in adhesion barriers, combined with numerous upcoming product launches, will fuel revenues in the US adhesion barrier market. Exceeding $550 million by 2013, the adhesion barrier market will experience a compound annual growth rate of almost 25% over the next five years.
It is estimated that the cost of treating adhesiolysis (the surgical removal of adhesions) in the US is over $2 billion annually. Due in part to the narrow range of approved indications for currently available products, the US adhesion barrier market remains underpenetrated; however, interest in these products is expanding rapidly as hospitals and surgeons realize the many benefits of using an adhesion barrier in surgical procedures. This interest will prompt a growing number of competitors to enter the US adhesion barrier market in the coming years.
The arrival of new adhesion barriers will expand indications, and the associated favorable clinical data that supplement product approvals, will boost surgeon awareness and drive adoption. Improved awareness will further be bolstered by continuing innovation and intensifying competition from market competitors, contributing to unit growth and adhesion barrier market expansion over the next five years.
"Following the removal of Gliatech's ADCON-L, FzioMed's Oxiplex/SP adhesion barrier was slated to be the first such product approved for spinal applications in the US," says Kevin Flewwelling, Manager of Orthopedics at MRG. "But, due to the product's unfavorable approval vote from the FDA's Orthopaedic & Rehabilitative Devices Panel in July of 2008, several companies have demonstrated renewed interest in developing an adhesion barrier approved for use in the lucrative US spine market."
MRG's US Markets for Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers 2009 report provides in-depth coverage of the surgical hemostat, internal tissue sealant, and adhesion barrier markets. Competitors covered include Baxter BioSurgery, Covidien, CryoLife, Davol (a subsidiary of C.R. Bard), Ethicon (a Johnson & Johnson company), Genzyme Biosurgery, King Pharmaceuticals, MAST Biosurgery, Orthovita, Pfizer, and many more.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized solutions.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Amy Krohn
Millennium Research Group
416-364-7776 x101
akrohn@mrg.net
Elizabeth Marshall
Decision Resources Inc.
781-296-2563
emarshall@dresources.com
